The shortage of available donor allografts continues to provoke a health care crisis and provides the rationale for continued xenotransplantation research. We are attempting to address these issues by inducing transplantation tolerance across discordant xenogeneic barriers in non-human primates. Our strategy utilizes composite vascularized thymic-renal grafts from GalT-KO swine. During the most recent project period (late 2004-2008), we markedly decreased the complication rate in the induction period with a """"""""modified regimen,"""""""" which eliminated steroids and whole body irradiation. Our most significant findings are (1) Extended average survival of life-supporting kidney xenograft recipients to greater than 50 days under the modified immunosuppression regimen as compared to 33 days under the original protocol;(2) Reproducible in vitro evidence for donor-specific tolerance;and (3) Demonstration of CD4/CD8 double positive baboon xenothymocytes in transplanted pig thymic grafts, indicating baboon thymopoiesis, which had otherwise not been achieved in a large animal xenotransplant model. To our knowledge, these results represent the longest average survival of life-supporting xenografts and also provide novel in vitro evidence for tolerance in large animals. In order to make this approach more clinically applicable, this proposal will address remaining crucial concerns of tolerance induction, immune suppression, and issues with renal xenograft function in baboons that may be caused by molecular incompatibilities across species.
In Aim 1, we will first confirm immunologic tolerance induced by xenogeneic porcine vascularized thymic grafts and eliminate maintenance immunosuppression using our most successful regimen. We will also attempt to achieve tolerance with a T-cell depletion based regimen in order to remove anfi-CD154 mAb and myelosuppressive drugs.
In Aim 2, we will assess in-vitro parameters of xenogeneic immunity before and after transplantation of vascularized thymic tissue. We will examine the fundamental cellular processes involved in the development and maintenance of tolerance.
In Aim 3, we will evaluate the cause of xenograft kidney proteinuria and develop preventive strategies. We will explore: 1) the utility of anti-non-Gal antibody removal prior to graft implantation;2) pharmacologic adjuvant vascular protective therapies shown to be clinically effective for treatment of vascular injury/proteinuria;and 3) the use of kidneys from GalT-KO pigs with additional transgenes, including hDAF, hCD39 and thrombomodulin. The success of a clinically applicable strategy would provide not only a limitless supply of donor organs but also opportunities for transplantation in patients unable to receive a transplant because of presensitization to allogeneic human donors.

Public Health Relevance

The cure for end stage organ disease is allo-transplantation;however, there is a critical organ donor shortage. We have previously demonstrated life supporting porcine renal xenograft survival up to 3 months in nonhuman primates by using innovative strategies of T-cell re-education through co-transplantation of a vascularized thymus with kidneys from genetically modified miniature swine. The clinical applicability unique to this proposal will allow us to address the remaining issues of tolerance induction, immunity and molecular incompatibilities across a xenogeniec barrier. The benefits of clinically applicable xenotransplantation include decreases in medical costs and limitless organ supply, as well as the ability to provide recipients previously unable to receive a transplant because of presensitization to human donors or recurrent disease (e.g Hepatitis C), with a life-saving organ.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-QV-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Yamada, Kazuhiko; Shah, Jigesh A; Tanabe, Tatsu et al. (2017) Xenotransplantation: Where Are We with Potential Kidney Recipients? Recent Progress and Potential Future Clinical Trials. Curr Transplant Rep 4:101-109
Giwa, Sebastian; Lewis, Jedediah K; Alvarez, Luis et al. (2017) The promise of organ and tissue preservation to transform medicine. Nat Biotechnol 35:530-542
Tena, Aseda A; Sachs, David H; Mallard, Christopher et al. (2017) Prolonged Survival of Pig Skin on Baboons After Administration of Pig Cells Expressing Human CD47. Transplantation 101:316-321
Chen, Bing; Fan, Wei; Zou, Jun et al. (2017) Complement Depletion Improves Human Red Blood Cell Reconstitution in Immunodeficient Mice. Stem Cell Reports 9:1034-1042
Sprangers, B; DeWolf, S; Savage, T M et al. (2017) Origin of Enriched Regulatory T Cells in Patients Receiving Combined Kidney-Bone Marrow Transplantation to Induce Transplantation Tolerance. Am J Transplant 17:2020-2032
Leonard, D A; Mallard, C; Albritton, A et al. (2017) Skin grafts from genetically modified ?-1,3-galactosyltransferase knockout miniature swine: A functional equivalent to allografts. Burns 43:1717-1724
Tanabe, T; Watanabe, H; Shah, J A et al. (2017) Role of Intrinsic (Graft) Versus Extrinsic (Host) Factors in the Growth of Transplanted Organs Following Allogeneic and Xenogeneic Transplantation. Am J Transplant 17:1778-1790
Yamada, Kazuhiko; Sykes, Megan; Sachs, David H (2017) Tolerance in xenotransplantation. Curr Opin Organ Transplant 22:522-528
Mastroianni, Melissa; Ng, Zhi Yang; Goyal, Ritu et al. (2017) Topical Delivery of Immunosuppression to Prolong Xenogeneic and Allogeneic Split-Thickness Skin Graft Survival. J Burn Care Res :
Tan, Shulian; Li, Yang; Xia, Jinxing et al. (2017) Type 1 diabetes induction in humanized mice. Proc Natl Acad Sci U S A 114:10954-10959

Showing the most recent 10 out of 185 publications